Omalizumab v placebo for childhood allergic asthma‡
| Outcomes | Omalizumab | Placebo | RBI (95% CI) | NNT (CI) |
|---|---|---|---|---|
| 75% to 100% reduction in BDP dose at 34 weeks | 65% | 50% | 32% (8 to 65) | 7 (4 to 23) |
| RRR (CI) | ||||
|---|---|---|---|---|
| ‡BDP = beclomethasone dipropionate. Other abbreviations defined in glossary; RBI, RRR, NNT, and CI calculated from information provided by author. | ||||
| Asthma exacerbations at 12 weeks | 18% | 39% | 53% (32 to 67) | 5 (4 to 10) |